phospho-MAPKAPK5 (Ser93) Polyclonal Antibody, Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-5505R-Cy7 |
| Product Name | phospho-MAPKAPK5 (Ser93) Polyclonal Antibody, Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse, Rat |
| Predicted Reactivity | Dog, Cow, Horse, Chicken |
| Specifications | |
| Conjugation | Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human MAPKAPK5 around the phosphorylation site of Ser93 |
| Modification Site | Ser93 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 8550 |
| Subcellular location | Cytoplasm, Nucleus |
| Synonyms | MAPKAPK5phospho S93; MAP kinase-activated protein kinase 5; MAPKAP kinase 5; MAPKAPK5; mitogen-activated protein kinase-activated protein kinase 5; p38-regulated/activated protein kinase. |
| Background | The serine/threonine kinase PRAK is activated in response to cellular stress and proinflammatory cytokines, through its phosphorylation by MAP kinases including MAPK1/ERK, MAPK14/p38 alpha, and MAPK11/p38 beta. PRAK has been reported to have a putative tumor suppressor function by mediating senescence upon activation by p38 in response to oncogenic ras. It is thought that phosphorylation of p53 by PRAK following activation of p38 MAPK by ras plays an important role in ras induced senescence and tumor suppression. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is phospho-MAPKAPK5 (Ser93) Polyclonal Antibody, Cy7 Conjugated (bs-5505R-Cy7) validated for, and at what dilution?
bs-5505R-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does phospho-MAPKAPK5 (Ser93) Polyclonal Antibody, Cy7 Conjugated (bs-5505R-Cy7) react with?
Tested reactivity: Human, Mouse, Rat. Predicted reactivity (expected from sequence homology but not yet tested): Dog, Cow, Horse, Chicken.
How should bs-5505R-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise phospho-MAPKAPK5 (Ser93) Polyclonal Antibody, Cy7 Conjugated (bs-5505R-Cy7)?
KLH conjugated synthetic phosphopeptide derived from human MAPKAPK5 around the phosphorylation site of Ser93
What are the excitation and emission wavelengths of the Cy7 conjugate (bs-5505R-Cy7)?
Cy7 on bs-5505R-Cy7: excitation / emission 743nm/767nm.